Researchers Explore Reliable Ways to Diagnose Alzheimer’s
Researchers explored how combining CSF analysis and amyloid PET imaging can improve the accuracy and efficiency of Alzheimer’s diagnosis.
Category: Dementias & Alzheimer’s
Dementias & Alzheimer’s
Latest
Dementias & Alzheimer’s
Latest
Time of Day Impacts Alzheimer’s Biomarker Levels
The time of day significantly affects Alzheimer’s biomarkers, highlighting the need for standardized blood sampling times.
Dementias & Alzheimer’s
Latest
Biosensor that Detects Dopamine May Help Screen for Neurological Conditions, Cancer
The plasmonic biosensor is capable of detecting dopamine from blood, offering a tool for screening cancers and neurological conditions.
New Test Can Detect Patients’ Risk of Harmful Side Effects from Alzheimer’s Drugs
A new PCR-based test accurately predicts Alzheimer’s patients’ genetic predisposition to side effects from anti-amyloid drugs.
Read More
FNIH Consortium Validates Blood Tests for Alzheimer’s Disease
Certain blood tests are as accurate as spinal taps and brain scans to detect amyloid plaques, potentially influencing Alzheimer’s diagnosis.
Read More
New Alzheimer’s Blood Test Available to Consumers
Apollo Health unveiled an Alzheimer’s disease test which uses three blood tests to detect Alzheimer’s pathology.
Read More
Beckman Coulter Receives pTau217 Antibody to Develop Alzheimer’s Test
ALZpath signed an agreement with Beckman Coulter to utilize its pTau217 antibody in a diagnostic test on the DxI 9000 Immunoassay Analyzer.
Read More
Dementia Diagnoses now Possible Using AI
Researchers have developed an AI tool for dementia diagnoses of 10 different types of the disease, including those with overlapping symptoms.
Read More
New High-Throughput Tech May Help Diagnose Elusive Neurodegenerative Disease
Researchers discovered a pattern in the spinal fluid of patients with progressive supranuclear palsy using high-throughput technology.
Read More
Alzheimer’s Association Revises Criteria for Diagnosis and Staging of Alzheimer’s
Newly revised diagnostic criteria for Alzheimer’s incorporates new research and biomarkers to better define and manage the condition.
Read More
C2N’s Precivity Tests Now Offered Through Mayo Clinic Labs
C2N Diagnostics partnered with Mayo Clinic to expand access to its Precivity tests, which detect amyloid plaques associated with Alzheimer’s.
Read More
Blood Markers Detect Rare Forms of Dementia
A study has demonstrated that blood markers can identify frontotemporal dementia (FTD), (ALS), and progressive supranuclear palsy (PSP).
Read More
Roche and ALZpath Partner on Alzheimer’s Blood Test
ALZpath and Roche will develop a blood test for Alzheimer’s diagnosis using the pTau217 antibody on the Roche Elecsys platform.
Read More
AI Tool Helps Spot Mild Cognitive Decline in Spanish Speakers
A novel AI speech analysis tool successfully detected mild cognitive impairment and dementia in Spanish speakers.
Read More
Racial Disparities in Diagnosis for Dementia Symptoms
White and Hispanic people are most likely to be diagnosed with behavioral symptoms of dementia, according to USC study.
Read More
Biomarker Can diagnose Asymptomatic Alzheimer’s
A study has identified a new biomarker for asymptomatic Alzheimer’s disease, potentially enabling earlier diagnosis and treatment.
Read More
Quest Adds New Blood Biomarker to Alzheimer’s Testing Portfolio
Quest Diagnostics expanded its AD-Detect portfolio of Alzheimer’s tests by adding a blood biomarker test for early disease diagnosis.
Read More
Labcorp’s New Blood Test Identifies Neurodegenerative Diseases and Brain Injuries
Labcorp’s new blood test detects glial fibrillary acidic protein, a crucial biomarker for identifying neurodegenerative diseases.
Read More